Krystal Biotech's (KRYS) "Buy" Rating Reaffirmed at HC Wainwright

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $361.00 target price on the stock. HC Wainwright's target price indicates a potential upside of 8.77% from the company's previous close.

Other analysts have also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a "buy" rating and set a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. TD Cowen upped their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a "buy" rating in a research report on Thursday, June 18th. Wall Street Zen cut Krystal Biotech from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a report on Wednesday, September 23rd. Finally, Royal Bank Of Canada started coverage on Krystal Biotech in a report on Friday, August 14th. They set an "outperform" rating and a $400.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and an average price target of $377.20.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $1.21 on Thursday, reaching $331.90. 129,602 shares of the stock were exchanged, compared to its average volume of 327,727. Krystal Biotech has a one year low of $183.03 and a one year high of $382.54. The firm has a market cap of $9.82 billion, a PE ratio of 41.59 and a beta of 0.50. The firm's 50 day moving average is $340.46 and its 200-day moving average is $322.60.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating analysts' consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. The firm had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. On average, equities research analysts expect that Krystal Biotech will post 7.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Dino Rossi sold 25,000 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company's stock.

Institutional Trading of Krystal Biotech

Several institutional investors and hedge funds have recently bought and sold shares of KRYS. Silvant Capital Management LLC purchased a new stake in Krystal Biotech in the second quarter worth about $30,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Krystal Biotech during the 2nd quarter valued at about $46,000. Western Wealth Management LLC purchased a new stake in Krystal Biotech during the 1st quarter valued at $34,000. USA Financial Formulas purchased a new stake in Krystal Biotech during the first quarter valued at $44,000. Finally, GK Wealth Management LLC purchased a new position in shares of Krystal Biotech in the third quarter worth approximately $59,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech's lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.